🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Screening for Intrapartum Fetal Compromise Using Placental Biomarkers

Recruitingn/aAges 18 Years - anyFemaleIRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT07258329 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to investigate the association between placental markers (sFlt-1, PlGF, and the sFlt-1/PlGF ratio) and intrapartum fetal compromise, assessed on the basis of the cardiotocographic tracing.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Gestational age ≥ 32 weeks * Obtaining informed consent for participation in the study and for the processing of personal data * Pregnant patients with an indication to perform placental marker testing as part of routine clinical practice * Patients who will deliver at the Obstetrics Units of the participating centers Exclusion Criteria: \- Absolute contraindications to vaginal delivery (placenta previa, vasa previa, placenta accreta, previous myomectomy)
💊

What it tests

  • Not listed
📍

Where

2 sites
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy
IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy